Huntsman Richard James, Tang-Wai Richard, Acton Bryan, Alcorn Jane, Lyon Andrew William, Mousseau Darrell David, Seifert Blair, Laprairie Robert, Prosser-Loose Erin, Hanuš Lumir Ondrej
Cannabinoid Research Initiative of Saskatchewan (CRIS), University of Saskatchewan, Saskatoon, Saskatchewan.
Division of Pediatric Neurology, Department of Pediatrics, University of Saskatchewan, Saskatoon, Saskatchewan.
Paediatr Child Health. 2018 Sep;23(6):368-373. doi: 10.1093/pch/pxy036. Epub 2018 Apr 5.
The plant produces over 140 known cannabinoids. These chemicals generate considerable interest in the medical research community for their possible application to several intractable disease conditions. Recent reports have prompted parents to strongly consider Cannabis products to treat their children with drug resistant epilepsy. Physicians, though, are reluctant to prescribe Cannabis products due to confusion about their regulatory status and limited clinical data supporting their use. We provide the general paediatrician with a brief review of cannabinoid biology, the literature regarding their use in children with drug resistant epilepsy, the current Health Canada and Canadian Paediatric Society recommendations and also the regulations from the physician regulatory bodies for each province and territory. Given the complexities of conducting research on Cannabis products for children with epilepsy, we also discuss outstanding research objectives that must be addressed to support Cannabis products as an accepted treatment option for children with refractory epilepsy.
这种植物能产生超过140种已知的大麻素。这些化学物质因其可能应用于多种难治性疾病状况而在医学研究界引起了极大兴趣。最近的报道促使家长们强烈考虑使用大麻产品来治疗患有耐药性癫痫的孩子。然而，由于对其监管状态的困惑以及支持其使用的临床数据有限，医生们不愿开具大麻产品的处方。我们为普通儿科医生简要回顾了大麻素生物学、关于其在耐药性癫痫儿童中使用的文献、加拿大卫生部和加拿大儿科学会的当前建议，以及每个省和地区医生监管机构的规定。鉴于对癫痫儿童使用大麻产品进行研究的复杂性，我们还讨论了为支持大麻产品成为难治性癫痫儿童的可接受治疗选择而必须解决的突出研究目标。
